Home

Search Abstracts

Browse Oral Sessions

Browse Poster Sessions

Session 13-Themed Discussion Themed Discussion: Pharmacogenomics of Drug Toxicity Tuesday, 1-2 pm; Room 613       593 Genome-wide Association Study of Plasma Efavirenz Pharmacokinetics in ACTG Protocols B Grady1, M Ritchie2, E Acosta3, G Morse4, E Daar5, R Gulick6, G Robbins7, P McLaren8, David Haas1, and ACTG 1Vanderbilt Univ Sch of Med, Nashville, TN, US; 2Pennsylvania State Univ, Univ Park, US; 3Univ of Alabama at Birmingham Sch of Med, US; 4Univ at Buffalo, State Univ of New York, US; 5Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance, CA, US; 6Weill Cornell Med Coll, New York, NY, US; 7Harvard Univ, Boston, MA, US; and 8Harvard Univ, Broad Inst of MIT and Harvard, Cambridge, MA, US       594 HLA-B*3505 and Female Gender Were Strong Predictive Factors of Modifying the First ARV Drug Regimen Due to Adverse Effect: Thailand Naho Tsuchiya1,2, P Pathipvanich3, A Rojanawiwat4, W Auwanit4, P Sawanpanyalert4, and K Ariyoshi1,2 1Inst of Tropical Med, Nagasaki Univ, Japan; 2Global COE Prgm, Nagasaki Univ, Japan; 3Lampang Hosp, Thailand; and 4Natl Inst of Hlth, Ministry of Publ Hlth, Nonthaburi, Thailand       595 Impact of Host Genetics on Dyslipidemia of HIV+ ARV-naïve Patients Starting HAART including Protease Inhibitors or NNRTI Lander Egaña-Gorroño1, E Martinez2, I Pérez2, T Escribà1, J Gatell1,2, and M Arnedo1 1IDIBAPS, Barcelona, Spain and 2Hosp Clin Barcelona, Univ of Barcelona, Spain       596 Contribution of Genetic Background to Acute Coronary Artery Disease Events in HIV+ Individuals: The MAGNIFICENT Consortium Margalida Rotger1, T Junier2, T Glass3, J Neaton4,5, J Lundgren5,6, H Bucher3, J Fellay1,2, A Telenti1, P Tarr3, and MAGNIFICENT Consortium, INSIGHT and the Swiss HIV Cohort Study 1Univ of Lausanne, Switzerland; 2École Polytechnique Fédérale de Lausanne, Switzerland; 3Univ of Basel, Switzerland; 4Univ of Minnesota, Minneapolis, US; 5Intl Network for Strategic Initiatives in Global HIV Trials; and 6Univ of Copenhagen, Denmark       597 Premature Discontinuation of Atazanavir/ritonavir and UGT1A1 Variants: ACTG Protocol A5202 Heather Ribaudo1, E Daar2, C Tierney1, G Morse3, K Mollan1, P Sax4, M Fischl5, A Collier6, D Haas7, and ACTG 1Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US; 2Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance, CA, US; 3Univ at Buffalo, State Univ of New York, US; 4Brigham and Women`s Hosp, Boston, MA, US; 5Univ of Miami Miller Sch of Med, FL, US; 6Univ of Washington, Seattle, US; and 7Vanderbilt Univ Sch of Med, Nashville, TN, US       598 Cost-effectiveness Analysis of UGT1A1 Genetic Screening to Inform Initial ARV Prescribing Bruce Schackman1, D Haas2, J Becker3, B Berkowitz3, P Sax4,5, E Daar6, H Ribaudo7, and K Freedberg3,5 1Weill Cornell Med Coll, New York, NY, US; 2Vanderbilt Univ Sch of Med, Nashville, TN, US; 3Massachusetts Gen Hosp, Boston, US; 4Brigham and Women`s Hosp, Boston, MA, US; 5Harvard Med Sch, Boston, MA, US; 6Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance, CA, US; and 7Harvard Sch of Publ Hlth, Boston, MA, US